Ongoing Clinical Trials

Indication
Institution
Department
Principal Investigator
Protocol Title
TMU-JIRB No. Protocol Title Indication Institution Department Principal Investigator Contact
N202201030 A randomized, evaluator-blinded, controlled study to evaluate the safety and clinical performance of OIF/β-TCP in patients with open tibial fractures in need of bone grafting. Tibial fracture SHH Orthopedics Chih-Hwa Chen Shin-Jiun Tsai
02-2490088 #8788
N202210066 A phase I-II, dose-escalation, double-blinded, placebo-controlled, and dose-finding study to evaluate the safety and efficacy of 2ccPA in patients with osteoarthritis of the knee Knee Osteoarthritis (KOA) SHH Orthopedics Chih-Hwa Chen Shin-Jiun Tsai
02-2490088 #8788
N202210056 A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of Oral Ozanimod to Evaluate Efficacy and Long-term Safety in Chinese Participants with Moderately to Severely Active Ulcerative Colitis (UC) Ulcerative Colitis (UC) SHH Gastroenterology Ming-Yao Chen Jheng-Yi Liou
0979448117
N202208003 Patient-Reported Outcomes of Benralizumab in Real-World Use in Severe Eosinophilic Asthma Patients in Taiwan (BEAT) Asthma SHH Pulmonary Medicine Chen Kuan-Yuan Rong-Wei Jhou
0963969167
N202101017 Non-Interventional Collecting Evidences For ILD in Taiwan: Optimized Novel Therapy Interstitial lung disease SHH Pulmonary Medicine Tzu-Tao Chen Cing-Mei Chen
0970746956
N202201024 An open-label study to evaluate the effectiveness and safety of EZYPRO® in atrial fibrillation detection in nearly embolic stroke of undetermined source (ESUS) patient Atrial fibrillation SHH Neurology Lung Chan Shin-Jiun Tsai
02-2490088 #8788
N202205015 A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Multiple Doses of LT3001 Drug Product in Subjects with Acute Ischemic Stroke (AIS) Ischemic stroke SHH Neurology Lung Chan Shin-Jiun Tsai
02-2490088 #8788
N202305029 A multicenter, international, randomized, placebo controlled, double-blind, parallel group and event driven Phase 3 study of the oral FXIa inhibitor asundexian (BAY 2433334) for the prevention of ischemic stroke in male and female participants aged 18 years and older after an acute non-cardioembolic ischemic stroke or high-risk TIA Ischemic stroke SHH Neurology Lung Chan Shin-Jiun Tsai
02-2490088 #8788
N201905120 A phase III, open-label, randomized study of osimertinib with or without platinum plus pemetrexed chemotherapy, as first-line treatment in patients with epidermal growth factor receptor (EGFR) mutation-positive, locally advanced or metastatic non-small cell lung cancer (FLAURA2) Lung Cancer SHH Pulmonary Medicine Po-Hao Feng Rong-Wei Jhou
0963969166
N202303137 A Phase I/IIa Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GMXANTHO in Healthy Volunteers and to Investigate its Efficacy and Safety Profile in Atopic Dermatitis Patients. Atopic Dermatitis SHH Dermatology Chia-Lun Chou Ya-Chun Chang
0976909019
1 2 3 4 5 6 7 8 9 10 11 12 13 / 13

TOP